Zika Virus Antagonizes Type I Interferon Responses during Infection of Human Dendritic Cells

James R Bowen1,2, Kendra M Quicke1,2, Mohan S Maddur2,3

  • 1Department of Pediatrics, Division of Infectious Diseases, Emory University School of Medicine, Atlanta, Georgia, United States of America.

Plos Pathogens
|February 3, 2017
PubMed

Insights

Zika virus (ZIKV) infects human dendritic cells (DCs), evading immune responses by inhibiting type I interferon. Targeting the RIG-I pathway shows promise for controlling ZIKV replication in DCs.

Area of Science:

  • Virology
  • Immunology
  • Cell Biology

Background:

  • Zika virus (ZIKV) causes severe birth defects and neurological disorders.
  • Dendritic cells (DCs) are crucial in flavivirus infections, but ZIKV's interaction with DCs is unclear.
  • Understanding ZIKV-DC interplay is vital for developing antiviral strategies.

Purpose of the Study:

  • To investigate the interaction between Zika virus and human dendritic cells.
  • To determine how ZIKV affects DC function and immune signaling.
  • To identify potential therapeutic targets for ZIKV infection.

Main Methods:

  • Infection of human dendritic cells with contemporary and historic ZIKV isolates.
  • Analysis of viral replication, DC activation markers, cytokine secretion, and type I interferon response.
  • Assessment of STAT1/STAT2 phosphorylation and RIG-I agonist/type I interferon treatment effects.

Main Results:

  • Human DCs supported productive ZIKV infection with variable replication kinetics between donors and strains.
  • ZIKV infection led to minimal DC activation and cytokine secretion, and inhibited type I interferon protein translation.
  • ZIKV antagonized type I interferon signaling, but RIG-I agonist treatment potently restricted viral replication.

Conclusions:

  • ZIKV subverts DC immunogenicity by evading type I interferon responses.
  • The RIG-I signaling pathway remains capable of inducing an antiviral state against ZIKV.
  • Targeting the RIG-I pathway presents a potential therapeutic strategy for ZIKV infection.